Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
Total Valuation
Day One Biopharmaceuticals has a market cap or net worth of $2.20B. The enterprise value is $2.01B.
Market Cap$2.20B
Enterprise Value$2.01B
Share Statistics
Day One Biopharmaceuticals has 103,297,690 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding103,297,690
Owned by Insiders1.60%
Owned by Institutions13.04%
Financial Efficiency
Day One Biopharmaceuticals’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -28.03%.
Return on Equity (ROE)-0.24
Return on Assets (ROA)-0.21
Return on Invested Capital (ROIC)-28.03%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee873.93K
Profits Per Employee-592.94K
Employee Count181
Asset Turnover0.31
Inventory Turnover2.72
Valuation Ratios
The current PE Ratio of Day One Biopharmaceuticals is ―. Day One Biopharmaceuticals’s PEG ratio is -4.58.
PE Ratio―
PS Ratio6.09
PB Ratio2.18
Price to Fair Value2.18
Price to FCF-9.26
Price to Operating Cash Flow-21.23
PEG Ratio-4.58
Income Statement
In the last 12 months, Day One Biopharmaceuticals had revenue of 158.18M and earned -107.32M in profits. Earnings per share was -1.04.
Revenue158.18M
Gross Profit140.97M
Operating Income-127.75M
Pretax Income-109.30M
Net Income-107.32M
EBITDA-105.82M
Earnings Per Share (EPS)-1.04
Cash Flow
In the last 12 months, operating cash flow was -103.76M and capital expenditures -3.82M, giving a free cash flow of -107.58M billion.
Operating Cash Flow-103.76M
Free Cash Flow-107.58M
Free Cash Flow per Share-1.04
Dividends & Yields
Day One Biopharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.61
52-Week Price Change145.79%
50-Day Moving Average12.00
200-Day Moving Average8.58
Relative Strength Index (RSI)82.50
Average Volume (3m)5.45M
Important Dates
Day One Biopharmaceuticals upcoming earnings date is May 13, 2026, After Close (Confirmed).
Last Earnings DateFeb 24, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Day One Biopharmaceuticals as a current ratio of 8.02, with Debt / Equity ratio of 0.63%
Current Ratio8.02
Quick Ratio7.91
Debt to Market Cap<0.01
Net Debt to EBITDA1.84
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Day One Biopharmaceuticals has paid -1.98M in taxes.
Income Tax-1.98M
Effective Tax Rate0.02
Enterprise Valuation
Day One Biopharmaceuticals EV to EBITDA ratio is -7.27, with an EV/FCF ratio of -7.39.
EV to Sales4.86
EV to EBITDA-7.27
EV to Free Cash Flow-7.39
EV to Operating Cash Flow-7.41
Balance Sheet
Day One Biopharmaceuticals has $441.11M in cash and marketable securities with $2.79M in debt, giving a net cash position of $438.32M billion.
Cash & Marketable Securities$441.11M
Total Debt$2.79M
Net Cash$438.32M
Net Cash Per Share$4.24
Tangible Book Value Per Share$4.09
Margins
Gross margin is 89.12%, with operating margin of -80.76%, and net profit margin of -67.85%.
Gross Margin89.12%
Operating Margin-80.76%
Pretax Margin-69.10%
Net Profit Margin-67.85%
EBITDA Margin-66.90%
EBIT Margin-69.10%
Analyst Forecast
The average price target for Day One Biopharmaceuticals is $20.86, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$20.86
Price Target Upside-1.93% Downside
Analyst ConsensusHold
Analyst Count9
Revenue Growth Forecast31.11%
EPS Growth Forecast-46.75%